Dissecting myeloid cell-mediated resistance to immune checkpoint blockade in bladder cancer
剖析膀胱癌中骨髓细胞介导的免疫检查点阻断抵抗
基本信息
- 批准号:10380068
- 负责人:
- 金额:$ 68.93万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2020
- 资助国家:美国
- 起止时间:2020-04-01 至 2025-03-31
- 项目状态:未结题
- 来源:
- 关键词:AtlasesAutomobile DrivingBindingBiological MarkersBiometryBladder NeoplasmBloodCell CommunicationCellsClinicalClinical TrialsComputational BiologyCoupledDataEventFibroblastsFutureGenesGenomicsGoalsImmuneImmunologistImmunologyImmunosuppressionMalignant NeoplasmsMalignant neoplasm of urinary bladderMapsMediatingMedical OncologyModelingMolecularMutationMyelogenousMyeloid CellsNatural Killer CellsOncologistOutcomePatientsPopulationPositioning AttributeResearch PersonnelResistanceResolutionResourcesRoleSpecimenT-LymphocyteTranslational ResearchTumor TissueUrineUrologistUrologyanti-PD-1/PD-L1anti-PD-L1 antibodiesbiomarker discoverycancer typecheckpoint inhibitionclinically relevantcohortexperiencegenetic signatureimmune checkpoint blockademacrophagemonocytemultidisciplinarymuscle invasive bladder cancernew therapeutic targetnovel markerpatient subsetspredictive markerresponsesingle-cell RNA sequencingtherapeutic targettranscriptomicstumor
项目摘要
Immune checkpoint inhibition (CPI) with anti-PD-1/PD-L1 antibodies has changed the treatment
landscape for several types of cancers including bladder cancer. In patients with advanced bladder cancer,
CPI can induce unprecedented durable responses. However, only a subset of patients responds to such
treatment necessitating a better understanding of mechanisms of primary resistance to facilitate the
identification of predictive biomarkers and rational combination approaches. We used an integrative approach
to identify biomarkers in a large clinical trial cohort of patients with metastatic bladder cancer that are
independently associated with response/resistance to CPI beyond tumor mutational burden (TMB) alone. We
identified three key gene modules derived from pre-treatment tumor transcriptomic data: a “good immune”
module associated with response to CPI, a stromal module associated with resistance to CPI, and a “bad
immune” module also associated with resistance to CPI, but that appears to mediate the negative impact of
the stromal module upon outcomes with CPI. Using single cell RNA sequencing data generated from fresh
bladder cancer specimens to dissect the cellular components and molecular interactions responsible for
expression of these 3 gene modules, we determined that the “good immune” module emanates largely from T-
cells and NK cells, the stromal module emanates from cancer-associated fibroblasts (CAFs), and the “bad
immune” module emanates predominantly from monocytes-macrophages (MΦ). We hypothesize that myeloid
cells drive primary resistance to CPI in bladder cancer. We further hypothesize that comprehensive cellular
and molecular maps of bladder cancer will facilitate identification of precise monocyte-MΦ subpopulations, and
CAF-myeloid-T-cell interactions, that can be leveraged to define novel biomarkers and therapeutic targets.
With access to a unique set of clinical trial cohorts that will provide tumor tissue, blood and urine
specimens as well as outcome data to CPI, we are uniquely positioned to: (Aim 1) Dissect gene modules
associated with response/resistance to CPI using high resolution maps of the cellular and molecular landscape
of muscle-invasive bladder cancer; Aim 2: Define the role of “bad immune” module genes in governing
monocyte-MΦ-mediated immune suppression; Aim 3: Refine and validate a monocyte-MΦ-related gene
signature as a biomarker of CPI resistance in clinical trial cohorts.
This proposal comprises an integrated network of multi-disciplinary collaborative investigators (GU
oncologists, urologists, immunologists and bioinformaticians) to accelerate translational research and
maximize future clinical benefits. These efforts will lead to the discovery of biomarkers, and potential
therapeutic targets, to extend the benefits of CPI beyond the 15-20% of patients with advanced bladder cancer
that respond to treatment.
使用抗 PD-1/PD-L1 抗体进行免疫检查点抑制 (CPI) 改变了治疗方法
包括膀胱癌在内的多种癌症的景观。在晚期膀胱癌患者中,
CPI 可以引发前所未有的持久反应。然而,只有一小部分患者对这种反应有反应
治疗需要更好地了解原发耐药机制,以促进
预测生物标志物的识别和合理的组合方法。我们采用了综合方法
在转移性膀胱癌患者的大型临床试验队列中鉴定生物标志物
除了肿瘤突变负荷(TMB)之外,与对 CPI 的反应/耐药独立相关。我们
确定了来自治疗前肿瘤转录组数据的三个关键基因模块:“良好的免疫”
与 CPI 反应相关的模块、与 CPI 抵抗相关的基质模块以及“坏”模块
免疫”模块也与抵抗 CPI 相关,但这似乎可以调节 CPI 的负面影响
基质模块根据 CPI 的结果。使用新鲜的单细胞 RNA 测序数据
膀胱癌标本来剖析负责的细胞成分和分子相互作用
通过对这 3 个基因模块的表达进行分析,我们确定“良好的免疫”模块主要来自 T-
细胞和 NK 细胞,基质模块源自癌症相关成纤维细胞 (CAF),而“坏细胞”
“免疫”模块主要源自单核细胞-巨噬细胞 (MΦ)。我们假设骨髓细胞
细胞驱动膀胱癌对 CPI 的初级抵抗。我们进一步假设综合细胞
膀胱癌的分子图谱将有助于精确识别单核细胞-MΦ亚群,以及
CAF-骨髓-T 细胞相互作用,可用于定义新的生物标志物和治疗靶点。
可以获得一组独特的临床试验队列,这些队列将提供肿瘤组织、血液和尿液
样本以及 CPI 结果数据,我们具有独特的定位:(目标 1)剖析基因模块
使用细胞和分子景观的高分辨率图与 CPI 的反应/抵抗相关
肌层浸润性膀胱癌;目标 2:定义“不良免疫”模块基因在调控中的作用
单核细胞-MΦ介导的免疫抑制;目标 3:精炼和验证单核细胞 MΦ 相关基因
签名作为临床试验队列中 CPI 抵抗的生物标志物。
该提案包括一个多学科协作研究人员的综合网络(GU
肿瘤学家、泌尿科医生、免疫学家和生物信息学家)加速转化研究和
最大限度地提高未来的临床效益。这些努力将导致生物标志物的发现,以及潜在的
治疗目标,将 CPI 的益处扩大到 15-20% 的晚期膀胱癌患者
对治疗有反应。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Nina Bhardwaj其他文献
Nina Bhardwaj的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Nina Bhardwaj', 18)}}的其他基金
The Tisch Cancer Institute (TCI) Paul Calabresi K12 Career Development Award for Clinical Oncology
蒂施癌症研究所 (TCI) Paul Calabresi K12 临床肿瘤学职业发展奖
- 批准号:
10434380 - 财政年份:2022
- 资助金额:
$ 68.93万 - 项目类别:
The Tisch Cancer Institute (TCI) Paul Calabresi K12 Career Development Award for Clinical Oncology
蒂施癌症研究所 (TCI) Paul Calabresi K12 临床肿瘤学职业发展奖
- 批准号:
10623252 - 财政年份:2022
- 资助金额:
$ 68.93万 - 项目类别:
Dissecting myeloid cell-mediated resistance to immune checkpoint blockade in bladder cancer
剖析膀胱癌中骨髓细胞介导的免疫检查点阻断抵抗
- 批准号:
10652272 - 财政年份:2020
- 资助金额:
$ 68.93万 - 项目类别:
Effect of SARS-CoV-2 on clinical course and NK cells in patients receiving immunotherapy
SARS-CoV-2 对接受免疫治疗的患者临床病程和 NK 细胞的影响
- 批准号:
10203557 - 财政年份:2020
- 资助金额:
$ 68.93万 - 项目类别:
Matrix metalloproteinase-2 modulates inflammation via TLR2
基质金属蛋白酶-2 通过 TLR2 调节炎症
- 批准号:
8777819 - 财政年份:2014
- 资助金额:
$ 68.93万 - 项目类别:
相似海外基金
Establishment of a method for evaluating automobile driving ability focusing on frontal lobe functions and its application to accident prediction
以额叶功能为中心的汽车驾驶能力评价方法的建立及其在事故预测中的应用
- 批准号:
20K07947 - 财政年份:2020
- 资助金额:
$ 68.93万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Evaluation of the Effectiveness of Multi-Professional Collaborative Assessment of Cognitive Function and Automobile Driving Skills and Comprehensive Support
认知功能与汽车驾驶技能多专业协同评估效果评价及综合支持
- 批准号:
17K19824 - 财政年份:2017
- 资助金额:
$ 68.93万 - 项目类别:
Grant-in-Aid for Challenging Research (Exploratory)
Development of Flexible Automobile Driving Interface for Disabled People
残疾人灵活汽车驾驶界面开发
- 批准号:
25330237 - 财政年份:2013
- 资助金额:
$ 68.93万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Automobile driving among older people with dementia: the effect of an intervention using a support manual for family caregivers
患有痴呆症的老年人的汽车驾驶:使用家庭护理人员支持手册进行干预的效果
- 批准号:
23591741 - 财政年份:2011
- 资助金额:
$ 68.93万 - 项目类别:
Grant-in-Aid for Scientific Research (C)